Primary Sjögren’s syndrome: Extraglandular manifestations and hydroxychloroquine therapy
| Autor: | D. S. Klajn, P. Pucci, V. Martire, G. Crespo, L. Santiago, R. Chaparro del Moral, Julia Demarchi, N. Tamborenea, S. Velez, C. Crow, F. Zazzetti, Laura Raiti, N. Benzanquen, Oscar Rillo, C. Amitrano, A. Catalan Pellet, Anastasia Secco, M. A. Medina, Francisco Caeiro, Silvia Papasidero, Juan Pablo Pirola, J.C. Barreira, C. Asnal, M.M. Mayer |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Primary sclerosing cholangitis 03 medical and health sciences 0302 clinical medicine Primary biliary cirrhosis Rheumatology Hypergammaglobulinemia Internal medicine Sicca syndrome medicine Humans 030212 general & internal medicine Prospective cohort study Fatigue Purpura Retrospective Studies 030203 arthritis & rheumatology business.industry Incidence Raynaud Disease Retrospective cohort study Hydroxychloroquine General Medicine Middle Aged medicine.disease Sjogren's Syndrome Antirheumatic Agents Concomitant Physical therapy Female business medicine.drug |
| Zdroj: | Clinical Rheumatology. 36:2455-2460 |
| ISSN: | 1434-9949 0770-3198 |
| Popis: | The use of hydroxychloroquine (HCQ) in Primary Sjogren’s Syndrome (pSS) has been assessed in different studies over the last years, with conflicting results regarding its efficacy in sicca syndrome and extraglandular manifestations (EGM). The goal of this study was to compare the incidence rate of EGM in pSS patients with and without HCQ therapy. We performed a multicenter retrospective study, including patients with pSS (European classification criteria) with at least 1 year of follow-up. Subjects with concomitant fibromyalgia, autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis were excluded. Demographics and pSS characteristics were recorded. The EGM were defined by EULAR-SS disease activity index (ESSDAI). Patients were divided into two groups according to their use or not of HCQ therapy. We evaluated the use of HCQ and its relationship to EGM. HCQ therapy was defined as the continuous use of the drug for at least 3 months. A descriptive analysis of demographics and pSS characteristics was performed. We compared the incidence of EGM between groups defined by HCQ therapy using chi2 test or Fisher’s exact test. A total of 221 patients were included (97.3% women), mean age, 55.7 years (SD 14). Mean age at diagnosis, 48.8 years (SD 15); median disease duration, 60 months (IQR 35–84). One hundred and seventy patients (77%) received HCQ. About half of the patients had at least one EGM during the course of the disease, 20% of them developed an EGM before the onset of the sicca syndrome and 26% simultaneously with dryness symptom. Overall, EGM were less frequent in those on HCQ therapy (36.5% vs 63.5%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink